Guides on essential vitamins, minerals, and bioactive compounds. Research on magnesium, potassium, zinc, bioavailability, stacking strategies, and how to build an effective daily supplement protocol.
Specialized pro-resolving mediators (SPMs) — resolvins, protectins, and maresins — are enzymatically synthesized from EPA and DHA to actively terminate inflammation. Their deficiency drives chronic inflammatory disease.
The Na+/K+-ATPase consumes nearly a third of the body's resting energy budget to maintain the ion gradients that make life possible. Its decline drives neuronal hyperexcitability, arrhythmia, and cognitive aging.
Resolution of inflammation is not passive decay—it's an active biochemical program driven by specialized pro-resolving mediators (SPMs) synthesized from EPA and DHA. Here's what the science shows.
Vitamin K2 resolves the calcium paradox of aging — simultaneous arterial calcification and bone loss — by carboxylating Matrix Gla Protein and osteocalcin to direct calcium away from soft tissue and into the skeleton.
Specialized pro-resolving mediators (SPMs) — resolvins, protectins, and maresins derived from EPA and DHA — actively terminate inflammation through specific receptor pathways rather than passively suppressing it. This reframes how we understand omega-3 biology.
Specialized pro-resolving mediators (SPMs) — resolvins, protectins, and maresins derived from EPA and DHA — actively terminate inflammation through specific receptor pathways rather than passively suppressing it. This reframes how we understand omega-3 biology.
Magnesium is not just a generic mineral — it is the voltage-dependent plug inside every NMDA receptor. When intracellular Mg²⁺ falls, the gate fails, glutamate becomes excitotoxic, and synaptic plasticity collapses.
Magnesium isn't just a generic mineral — it's the voltage-dependent gatekeeper of NMDA receptors. Intracellular Mg²⁺ depletion drives excitotoxicity, impaired LTP, and accelerated cognitive decline.
Specialized pro-resolving mediators (SPMs) are bioactive lipid metabolites of EPA and DHA that actively orchestrate inflammation resolution. They don't suppress inflammation — they end it.
Oral NMN, oral NR, and direct NAD+ infusion produce strikingly different tissue distributions. Understanding the Slc12a8 transporter and first-pass metabolism explains why route of administration — not just dose — determines which organs actually see an NAD+ rise.